[go: up one dir, main page]

DK3038654T3 - Ny anvendelse - Google Patents

Ny anvendelse Download PDF

Info

Publication number
DK3038654T3
DK3038654T3 DK14761702.1T DK14761702T DK3038654T3 DK 3038654 T3 DK3038654 T3 DK 3038654T3 DK 14761702 T DK14761702 T DK 14761702T DK 3038654 T3 DK3038654 T3 DK 3038654T3
Authority
DK
Denmark
Prior art keywords
new use
new
Prior art date
Application number
DK14761702.1T
Other languages
English (en)
Inventor
Victor Chengwei Shi
Martin Lefkowitz
Adel Remond Rizkala
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51494327&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3038654(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US2013/056680 external-priority patent/WO2015030711A1/en
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK3038654T3 publication Critical patent/DK3038654T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
DK14761702.1T 2013-08-26 2014-08-26 Ny anvendelse DK3038654T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2013/056680 WO2015030711A1 (en) 2013-08-26 2013-08-26 New use
US201461972933P 2014-03-31 2014-03-31
PCT/IB2014/064074 WO2015028941A1 (en) 2013-08-26 2014-08-26 New use

Publications (1)

Publication Number Publication Date
DK3038654T3 true DK3038654T3 (da) 2020-02-03

Family

ID=51494327

Family Applications (3)

Application Number Title Priority Date Filing Date
DK14761702.1T DK3038654T3 (da) 2013-08-26 2014-08-26 Ny anvendelse
DK23202190.7T DK4321157T3 (da) 2013-08-26 2014-08-26 Ny anvendelse af en kombination af en angiotensinreceptorblokker (arb) med en neutral endopeptidasehæmmer (nepi)
DK19202854.6T DK3626270T3 (da) 2013-08-26 2014-08-26 Behandling af kardiovaskulære sygdomme

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK23202190.7T DK4321157T3 (da) 2013-08-26 2014-08-26 Ny anvendelse af en kombination af en angiotensinreceptorblokker (arb) med en neutral endopeptidasehæmmer (nepi)
DK19202854.6T DK3626270T3 (da) 2013-08-26 2014-08-26 Behandling af kardiovaskulære sygdomme

Country Status (16)

Country Link
US (2) US20160213646A1 (da)
EP (4) EP3626270B1 (da)
JP (1) JP6097888B2 (da)
CY (1) CY1122531T1 (da)
DK (3) DK3038654T3 (da)
ES (3) ES2968541T3 (da)
FI (2) FI4321157T3 (da)
HR (3) HRP20200060T1 (da)
HU (3) HUE064634T2 (da)
LT (3) LT4321157T (da)
PL (3) PL3038654T3 (da)
PT (3) PT4321157T (da)
RS (3) RS66371B1 (da)
SI (3) SI4321157T1 (da)
SM (1) SMT202500001T1 (da)
WO (1) WO2015028941A1 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6097888B2 (ja) 2013-08-26 2017-03-15 ノバルティス アーゲー 新規使用
EP3253740A1 (en) * 2015-02-06 2017-12-13 Mylan Laboratories Ltd. Amorphous trisodium sacubitril valsartan and a process for the preparation thereof
WO2016193883A1 (en) * 2015-05-29 2016-12-08 Novartis Ag Sacubitril and valsartan for treating metabolic disease
CN106309388A (zh) * 2015-06-30 2017-01-11 深圳信立泰药业股份有限公司 一种用于心衰治疗的药物组合物及其制备方法
CN106491600A (zh) * 2015-09-06 2017-03-15 常州方楠医药技术有限公司 无定型沙库区比、缬沙坦或其药学上可接受的盐与药用辅料的组合物及其制备方法
WO2017036420A1 (zh) * 2015-09-06 2017-03-09 常州方楠医药技术有限公司 含沙库比曲和缬沙坦的药用组合物及其制备方法
CN107510653A (zh) * 2016-06-17 2017-12-26 常州爱诺新睿医药技术有限公司 一种含有无定型沙库比曲和缬沙坦的固体分散体的药用组合物及其制备方法
WO2017042700A1 (en) * 2015-09-07 2017-03-16 Sun Pharmaceutical Industries Limited Solid forms of valsartan and sacubitril
US20180303799A1 (en) * 2015-10-16 2018-10-25 Shenzhen Salubris Pharmaceuticals Co., Ltd An Oral Preparation for the Treatment of Cardiovascular Disease and Its Preparation Method
CN105330609B (zh) * 2015-12-07 2017-12-22 南京正大天晴制药有限公司 一种制备lcz696的方法
CA3010778C (en) 2016-02-03 2024-02-27 Novartis Ag Galenic formulations of organic compounds
CN106176681A (zh) * 2016-08-25 2016-12-07 泰力特医药（湖北）有限公司 一种抗心脏衰竭药物lcz696口服缓释微丸及其制备方法
US11382866B2 (en) 2017-07-06 2022-07-12 Mankind Pharma Ltd. Fixed dose pharmaceutical composition of valsartan and sacubitril
KR20210032437A (ko) * 2018-08-23 2021-03-24 노파르티스 아게 심부전의 치료를 위한 신규한 약제학적 용도
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
AU2020348813B2 (en) * 2019-09-20 2025-09-11 Shenzhen Salubris Pharmaceuticals Co. Ltd Uses of complex of angiotensin II receptor antagonist metabolite and NEP inhibitor in treating heart failure

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122010000024I1 (de) 1990-02-19 2010-07-08 Novartis Ag Acylverbindungen
US5217996A (en) 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
PT966282E (pt) * 1997-01-10 2003-10-31 Merck & Co Inc Uso de antagonistas da angiotensina ii para tratar a insuficiencia cardiaca sintomatica
ES2290429T3 (es) * 2002-01-17 2008-02-16 Novartis Ag Composiciones farmaceuticas que comprenden valsartan e inhibidores de nep.
JP4783733B2 (ja) * 2003-05-16 2011-09-28 ノバルティス アーゲー バルサルタンを含む医薬組成物
AR057882A1 (es) * 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
PT2217205E (pt) 2007-11-06 2015-06-08 Novartis Ag Composições farmacêuticas de dupla ação baseadas nos antagonistas dos recetores de angiotensina e inibidores (arb) da endopeptidase neutra (nep)
SG171780A1 (en) 2008-11-22 2011-07-28 Genentech Inc Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer
ES2702529T3 (es) * 2010-08-24 2019-03-01 Novartis Ag Una composición farmacéutica para uso en la prevención o tratamiento de la insuficiencia cardíaca en un mamífero que recibe terapia anticoagulante
JP6482462B2 (ja) 2012-08-24 2019-03-13 ノバルティス アーゲー 心房拡大又はリモデリングを特徴とする疾患を治療するためのｎｅｐ阻害剤
JP6097888B2 (ja) 2013-08-26 2017-03-15 ノバルティス アーゲー 新規使用
US20160206597A1 (en) * 2013-08-26 2016-07-21 Toni Lynne Bransford New Use

Also Published As

Publication number Publication date
FI3626270T3 (fi) 2024-01-11
ES2767084T3 (es) 2020-06-16
HUE047186T2 (hu) 2020-04-28
LT3038654T (lt) 2020-01-27
HUE064634T2 (hu) 2024-04-28
EP3626270A1 (en) 2020-03-25
PT3038654T (pt) 2020-02-04
HUE069419T2 (hu) 2025-03-28
EP4321157A3 (en) 2024-05-15
ES3001196T3 (es) 2025-03-04
HRP20241763T1 (hr) 2025-03-14
FI4321157T3 (fi) 2025-01-20
ES2968541T3 (es) 2024-05-10
US20160213646A1 (en) 2016-07-28
EP4321157B1 (en) 2024-10-23
JP2016528303A (ja) 2016-09-15
SI4321157T1 (sl) 2025-03-31
CY1122531T1 (el) 2021-01-27
DK4321157T3 (da) 2024-12-16
SI3626270T1 (sl) 2024-03-29
DK3626270T3 (da) 2024-01-15
SMT202500001T1 (it) 2025-03-12
EP3038654A1 (en) 2016-07-06
JP6097888B2 (ja) 2017-03-15
WO2015028941A1 (en) 2015-03-05
EP4512397A2 (en) 2025-02-26
PL3626270T3 (pl) 2024-04-08
HRP20240034T1 (hr) 2024-03-29
EP4512397A3 (en) 2025-05-14
RS65037B1 (sr) 2024-02-29
PT3626270T (pt) 2024-01-11
EP3626270B1 (en) 2023-10-11
PT4321157T (pt) 2025-01-08
LT4321157T (lt) 2025-01-10
PL4321157T3 (pl) 2025-03-03
EP4321157A2 (en) 2024-02-14
HRP20200060T1 (hr) 2020-04-03
US20210077461A1 (en) 2021-03-18
EP3038654B1 (en) 2019-10-30
PL3038654T3 (pl) 2020-05-18
LT3626270T (lt) 2024-01-25
RS66371B1 (sr) 2025-02-28
RS59816B1 (sr) 2020-02-28
SI3038654T1 (sl) 2020-02-28

Similar Documents

Publication Publication Date Title
NL301272I2 (nl) Fezolinetant
NL301120I2 (nl) dostarlimab
NL301247I2 (nl) mirikizumab
IL246002A0 (en) Novel methods
DK3342773T3 (da) Syk-hæmmere
DK3613453T3 (da) Fordamper
DK3038654T3 (da) Ny anvendelse
HRP20190228T1 (hr) Rubna traka
DK3077047T3 (da) Aramcholsalte
DK3052081T3 (da) Pastil
UY4325S (es) Otomana
DK3060460T3 (da) Saddel
DK3027598T3 (da) Oxoquinazolinyl-butanamidderivater
DK2956698T5 (da) Bindestrimler
DK2946640T3 (da) Langmuir-probe
EP2943489A4 (en) DEUTERATED MOMELOTINIB
DE102013106534B8 (de) Chromatographiepipettenspitze
EP2991647A4 (en) DEUTERED AMLEXANOX
EP2970310A4 (en) 5-BROMO-indirubins
EP2853297A4 (en) kendama
DK3071227T3 (da) Fiskevaccine
HUE036203T2 (hu) Spiro-oxazolonok
DE112014001252A5 (de) Aufbissschiene
PT3022200T (pt) Novos agentes antimaláricos
DK3086679T3 (da) Sportssko